| Literature DB >> 25448552 |
John R Eisenbrey1, Lorenzo Albala2, Michael R Kramer3, Nick Daroshefski2, David Brown2, Ji-Bin Liu4, Maria Stanczak4, Patrick O'Kane4, Flemming Forsberg4, Margaret A Wheatley2.
Abstract
Radiation therapy is frequently used in the treatment of malignancies, but tumors are often more resistant than the surrounding normal tissue to radiation effects, because the tumor microenvironment is hypoxic. This manuscript details the fabrication and characterization of an ultrasound-sensitive, injectable oxygen microbubble platform (SE61O2) for overcoming tumor hypoxia. SE61O2 was fabricated by first sonicating a mixture of Span 60 and water-soluble vitamin E purged with perfluorocarbon gas. SE61O2 microbubbles were separated from the foam by flotation, then freeze dried under vacuum to remove all perfluorocarbon, and reconstituted with oxygen. Visually, SE61O2 microbubbles were smooth, spherical, with an average diameter of 3.1 μm and were reconstituted to a concentration of 6.5 E7 microbubbles/ml. Oxygen-filled SE61O2 provides 16.9 ± 1.0 dB of enhancement at a dose of 880 μl/l (5.7 E7 microbubbles/l) with a half-life under insonation of approximately 15 min. In in vitro release experiments, 2 ml of SE61O2 (1.3 E8 microbubbles) triggered with ultrasound was found to elevate oxygen partial pressures of 100ml of degassed saline 13.8 mmHg more than untriggered bubbles and 20.6 mmHg more than ultrasound triggered nitrogen-filled bubbles. In preliminary in vivo delivery experiments, triggered SE61O2 resulted in a 30.4 mmHg and 27.4 mmHg increase in oxygen partial pressures in two breast tumor mouse xenografts.Entities:
Keywords: Microbubble; Oxygen delivery; Surfactant; Tumor hypoxia; Ultrasound contrast agent
Mesh:
Substances:
Year: 2014 PMID: 25448552 PMCID: PMC6457456 DOI: 10.1016/j.ijpharm.2014.11.023
Source DB: PubMed Journal: Int J Pharm ISSN: 0378-5173 Impact factor: 5.875